American Academy of Neurology Practice Parameters: Parkinson Disease Diagnosis and Treatment

Guideline Watch |
August 1, 2006

American Academy of Neurology Practice Parameters: Parkinson Disease Diagnosis and Treatment

  1. Joseph H. Friedman, MD

These parameters reveal many areas of missing evidence regarding PD diagnostic tools and treatments.

  1. Joseph H. Friedman, MD

An expert panel assembled by the American Academy of Neurology (AAN) has produced four articles reviewing published data on clinical aspects of Parkinson disease (PD) using the AAN’s published guidelines for Practice Parameter development. They grade the level of the evidence as A, B, C, or U (unknown). Some of the authors have received funding from, consulted for, or spoken on behalf of manufacturers of treatments for PD.

Regarding distinguishing PD from other parkinsonian disorders, the authors rate as useful (level B) assessments that measure levodopa and apomorphine responsiveness, olfaction, early falls, symmetry of motor symptoms and signs, disease progression, tremor, and autonomic function. Positive findings on some of these assessments support a diagnosis of PD; others support a diagnosis of a different parkinsonian disorder. Assessments using SPECT, PET, MRI, brain sonography, and physiologic studies have only level C or level U evidence. Older age at diagnosis and early akinetic rigidity are considered indicators of poor prognosis (level B). Early tremor is deemed a sign of relatively good prognosis, whereas postural instability portends worse prognosis (both level C).

One report covers the somewhat overlapping topics of neuroprotection and alternative therapies and documents a lack of evidence supporting these interventions. Vitamin E has level B evidence for no benefit for either neuroprotection or symptom treatment. There is insufficient evidence (level U) of neuroprotection with dopamine agonists, coenzyme Q10, rasagiline, amantadine, and thalamotomy. Levodopa has level B support for not accelerating disease progression. Exercise and the various therapies (speech, occupational, physical) have only level C support for symptom treatment; alternative treatments, level U support.

To treat fluctuations (“off” time), entacapone and rasagiline have level A evidence supporting efficacy; pramipexole, ropinirole, pergolide, and tolcapone, level B support; and apomorphine, cabergoline, and selegiline, level C support. There is level C evidence of ineffectiveness of bromocriptine and sustained-release carbidopa/levodopa. For levodopa dyskinesias, amantadine is the only drug treatment supported by acceptable data (level C). Similarly, only ropinirole has acceptable supporting evidence, albeit level C, for reducing “off” time. Deep brain stimulation of the subthalamic nucleus has only level C support for reducing dyskinesias and “off” time. Other stimulation targets have level U support.

Only amitriptyline use has support for depression treatment (level C), despite decades of concern about depression in PD; clozapine (level B) and quetiapine for psychosis treatment (level C); and rivastigmine and donepezil for dementia treatment (both level B). Evidence against olanzapine for psychosis is level B.

Comment

These impressive guidelines illustrate how little high-quality evidence exists regarding diagnosis and treatment of Parkinson disease. The guidelines define the panel’s level of confidence in each recommendation. The guidelines may not represent the best medical practice, and they do not pretend to. They do, however, force us to reflect on and distinguish what we know from what we think we know. The panel’s recommendations reflect data, and not necessarily judgment. To paraphrase an old saw, evidence of quality and quality of evidence are not the same. The guidelines must be interpreted accordingly.

Dr. Friedman is Director, NeuroHealth Parkinson’s Disease and Movement Disorders Center, Warwick, RI; and Clinical Professor, Department of Clinical Neurosciences, Brown Medical School, Providence, RI. He has received funds for lectures, consulting, or research over the past year from the following manufacturers of treatments for Parkinson disease: Astra Zeneca, Ovation, Acadia, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Teva, and Janssen.

Citation(s):

Reader Comments (1)

M R Hartley-Drabble

Revealing and believable analysis of the state of PD treatment. Excellent A,B,C,...system for value of comment. Ghrelin not mentioned!

Competing interests: None declared

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.